SK Bioscience saw its shares gain by its 160 per cent daily limit despite concerns over side effects of AstraZeneca Plc’s COVID-19 vaccine.
source https://www.smh.com.au/business/markets/astrazeneca-concerns-can-t-dent-korean-partner-s-stunning-market-debut-20210318-p57bvq.html?ref=rss&utm_medium=rss&utm_source=rss_feed
source https://www.smh.com.au/business/markets/astrazeneca-concerns-can-t-dent-korean-partner-s-stunning-market-debut-20210318-p57bvq.html?ref=rss&utm_medium=rss&utm_source=rss_feed
Tags:
Sydney Morning